$MEDI.NE - Clinical psychedelic company to keep an eye on More and more research studies are showing positive outcomes for using ketamine to treat depression in adults. A growing number of studies show that this “party drug” actually helps treat depression, post-traumatic stress disorder and other behavioural health/psychiatric disorders. Since ketamine has already been around for decades, it has been deemed safe, unlike many newer treatments and drugs, which still have unknown long-term effects.
https://www.google.ca/amp/s/abcnews.go.com/amp/Health/doctors-treating-depression-promise-ketamine-cheap-drug-approved/story%3fid=78928816
Recently, I’ve been looking into KetamineOne. It’s a unique clinical wellness company focusing on the patient experience and data collection to improve future visits.
- Uses a first-of-it’s-kind wearable device to track before, during, and post-treatment of patients during psychedelic-assisted therapies (adjust clinical processes based on patient reactions to specific treatments)
- Already established with 16 operating clinics across Canada with many more planned for North America (target at 30 clinics)
- Founded in 1997, they have both experience and history in the area
With growing revenues and more clinics opening up, $MEDI will stay in my portfolio for a while. They're currently holding at $1.50 with a market cap of $179M.
Here's the investor presentation: https://www.ketamine.one/investor-relations